Effects of a benidipine-based combination therapy on the risk of stroke according to stroke subtype: the COPE trial

Seiji Umemoto, Toshio Ogihara, Hiromi Rakugi, Masayasu Matsumoto, Kazuo Kitagawa, Kazuyuki Shimada, Jitsuo Higaki, Sadayoshi Ito, Hiromichi Suzuki, Yasuo Ohashi, Takao Saruta, Masunori Matsuzaki

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial compared the dihydropyridine T/L-type calcium channel blocker benidipine-based therapies when combined with an angiotensin receptor blocker (ARB), a β-blocker (BB) or a thiazide diuretic (TD). The results suggested that benidipine combined with a BB appeared to be less beneficial in reducing the risk of stroke compared with the benidipine-TD combination (hazard ratio (HR): 2.31, P=0.0109). We further evaluated the treatment effects on different stroke subtypes among the three benidipine-based regimens. The COPE trial was an investigator-initiated, multicenter study with PROBE design. Patients with atrial fibrillation or flutter were excluded from the study. All stroke events were subclassified with the Trial of Org 10 172 in Acute Stroke Treatment (TOAST) criteria. The total incidence of stroke was 4.7, hemorrhagic stroke was 1.6 and ischemic stroke was 2.5 per 1000 person-years. The incidence of lacunar stroke was 1.1, large-artery stroke was 0.6, cardioembolic stroke was 0.3, unknown ischemic type was 0.6 and transient ischemic attack was 0.6 per 1000 person-years. Although few differences in stroke subtypes were observed among the three treatment groups, multi-adjusted HRs for the incidence rates of all types of stroke, hemorrhagic stroke and ischemic stroke were significantly higher with the benidipine-BB regimen than with the benidipine-TD regimen. The incidence of both hemorrhagic and ischemic stroke in the benidipine-ARB regimen was not different compared with the other two treatment regimens. This prespecified sub-analysis suggested that a blood pressure-lowering therapy with a benidipine-TD regimen might be beneficial for hypertensive patients to prevent both hemorrhagic and ischemic stroke.

Original languageEnglish
Pages (from-to)1088-1095
Number of pages8
JournalHypertension Research
Volume36
Issue number12
DOIs
Publication statusPublished - 2013 Dec

Keywords

  • adrenergic β-antagonists
  • angiotensin antagonists
  • antihypertensive therapy/diuretics
  • calcium channel blockers
  • stroke

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effects of a benidipine-based combination therapy on the risk of stroke according to stroke subtype: the COPE trial'. Together they form a unique fingerprint.

  • Cite this

    Umemoto, S., Ogihara, T., Rakugi, H., Matsumoto, M., Kitagawa, K., Shimada, K., Higaki, J., Ito, S., Suzuki, H., Ohashi, Y., Saruta, T., & Matsuzaki, M. (2013). Effects of a benidipine-based combination therapy on the risk of stroke according to stroke subtype: the COPE trial. Hypertension Research, 36(12), 1088-1095. https://doi.org/10.1038/hr.2013.100